Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07444307Phase 1Recruiting

A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

Role: lead

NCT05987696Phase 1Completed

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Role: collaborator

NCT05601466Phase 1Terminated

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Role: collaborator

NCT05665075Phase 1Unknown

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Role: collaborator

NCT05665114Phase 1Unknown

Natural Killer(NK) Cell Therapy in r/r AML

Role: collaborator

NCT05379647Phase 1Unknown

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Role: collaborator

All 6 trials loaded